BioSpace News Archive

Clinical neuropathic pain expert Prof. Sommer and long-time pain pharma industry expert Dr. Langner to consult Algiax Pharmaceuticals in the development of AP-325 and further assetts.

Sartorius, a leading international partner of biopharmaceutical research and the industry, grew strongly in the first half of 2019, recording double-digit increases in sales revenue, order intake and earnings.

Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization, celebrates its 15th anniversary.

Dr. Reddy’s Laboratories Ltd. announced the launch of Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Release Tablets, USP, an over-the-counter (OTC) store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).

Cyxone, a Swedish biotech in autoimmune diseases, announced that the company has signed an agreement with EGeen Inc., a clinical research organization, for conducting its upcoming clinical phase IIb trial with Rabeximod in rheumatoid arthritis in select Eastern European countries.

The global vitamin D testing market is expected to post a CAGR of close to 5% during the period 2019-2023, according to the latest market research report by Technavio.

Halozyme Therapeutics, Inc. announced that Janssen-Cilag International NV has submitted an extension application to the European Medicines Agency for the subcutaneous delivery of DARZALEX® for patients with multiple myeloma.

Newly released care standards from the College’s Geriatric Surgery Verification Program are evidence-based and centered on goals that matter most to the patient

Several government bodies across the world are enforcing stringent regulations to tackle the adverse environmental effects of mercury emission.

Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Application (MAA) for SB8, a biosimilar candidate referencing AVASTIN® i (bevacizumab).